3SBio Inc (1530) – Strategy, SWOT and Corporate Finance Report
- Pages: 47
- Published: September 2023
- Report Code: MLPH55989FSA
3SBio Inc (1530) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology, and other disease conditions. The company distributes its products to hospitals, clinics and dialysis centers in China. The company sells its products in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, the Philippines, Paraguay, Thailand, Trinidad and Tobago. 3SBio is headquartered in Shenyang, Liaoning, China.
Scope
• Detailed information on 3SBio Inc required for business and competitor intelligence needs
• A study of the major internal and external factors affecting 3SBio Inc in the form of a SWOT analysis
• An in-depth view of the business model of 3SBio Inc including a breakdown and examination of key business segments
• News about 3SBio Inc, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of 3SBio Inc and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess 3SBio Inc as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on 3SBio Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
CapitalBio Corp
Harbin Pharmaceutical Group Holding Co Ltd
Hubei Guangji Pharmaceutical Co Ltd
Shandong Kexing Bioproducts Co Ltd
Nanjing Hencer Pharmaceutical Co Ltd
Zhejiang Raybow Pharmaceutical Co Ltd
China Intertrade Ltd
China Intertrade Ltd
Harbin Pharmaceutical Group Holding Co Ltd
Hubei Guangji Pharmaceutical Co Ltd
Kexing Biopharm Co Ltd
Zhejiang Raybow Pharmaceutical Co Ltd
CapitalBio Corp
Nanjing Hencer Pharmaceutical Co Ltd
Kirin Brewery Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.